Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models

被引:249
|
作者
Caldwell, A. S. L. [1 ]
Middleton, L. J. [1 ]
Jimenez, M. [1 ]
Desai, R. [1 ]
McMahon, A. C. [2 ]
Allan, C. M. [1 ]
Handelsman, D. J. [1 ]
Walters, K. A. [1 ]
机构
[1] Univ Sydney, ANZAC Res Inst, Androl Lab, Sydney, NSW 2139, Australia
[2] Univ Sydney, ANZAC Res Inst, Biogerontol Lab, Sydney, NSW 2139, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
FOLLICLE-STIMULATING-HORMONE; PRENATAL TESTOSTERONE; ANDROGEN EXCESS; SYNDROME PCOS; TARGETED DISRUPTION; LUTEINIZING-HORMONE; RHESUS-MONKEYS; CYCLING RATS; MICE; DEHYDROEPIANDROSTERONE;
D O I
10.1210/en.2014-1196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a range of reproductive, metabolic and endocrine defects including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism, and an increased risk of type 2 diabetes and cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its etiology remains unknown, and ethical and logistic constraints limit definitive experimentation in humans to determine mechanisms involved. In this study, we provide the first comprehensive characterization of reproductive, endocrine, and metabolic PCOS traits in 4 distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone (DHT, potent nonaromatizable androgen) treatment during days 16-18 of gestation, or long-term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or letrozole (aromatase inhibitor). Prenatal DHT-treated mature mice exhibited irregular estrous cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis, and adipocyte hypertrophy, but lacked overall changes in body-fat composition. Long-term DHT treatment induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16-week-old) females. Long-term DHT also increased body and fat pad weights and induced adipocyte hypertrophy and hypercholesterolemia. Long-term letrozole-treated mice exhibited absent or irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of PCOS, and displayed no metabolic features of PCOS. Long-term dehydroepiandrosterone treatment produced no PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated a breadth of ovarian, endocrine, and metabolic features of human PCOS and provides the best mouse model for experimental studies of PCOS pathogenesis.
引用
收藏
页码:3146 / 3159
页数:14
相关论文
共 50 条
  • [21] SEXUAL DESIRE IN HYPERANDROGENIC WOMEN WITH POLYCYSTIC OVARY SYNDROME
    Rellini, A. H.
    Stratton, N.
    Martini, E.
    Terreno, E.
    Santamaria, V
    Nappi, R. E.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 154 - 154
  • [22] Metabolic endocrine correlation of the dermatological manifestations in the polycystic ovary syndrome
    Hernandez Marin, Imelda
    Nunez Rodriguez, Marisela Adriana
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 129 - 130
  • [23] Endocrine metabolic disorders of the dermatologic manifestation in the polycystic ovary syndrome
    Nunez, Rodriguez M. A.
    Hernandez, Marin, I
    Valle, Molina L.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2016, 38 (01): : 163 - 167
  • [24] Is there a role for leptin in the endocrine and metabolic aberrations of polycystic ovary syndrome?
    Gennarelli, G
    Holte, J
    Wide, L
    Berne, C
    Lithell, H
    HUMAN REPRODUCTION, 1998, 13 (03) : 535 - 541
  • [25] Metabolic and Endocrine Characteristics of Indian Women with Polycystic Ovary Syndrome
    Kumar, Amar Nagesh
    Naidu, Jupalle Nagaiah
    Satyanarayana, Uppala
    Ramalingam, Krishnan
    Anitha, Medabalmi
    INTERNATIONAL JOURNAL OF FERTILITY & STERILITY, 2016, 10 (01) : 22 - 28
  • [26] Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
    Susan Sam
    David A. Ehrmann
    Diabetologia, 2017, 60 : 1656 - 1661
  • [27] Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
    Sam, Susan
    Ehrmann, David A.
    DIABETOLOGIA, 2017, 60 (09) : 1656 - 1661
  • [28] Laparoscopic surgery in polycystic ovary syndrome: Reproductive and metabolic effects
    Seow, Kok-Min
    Juan, Chi-Chang
    Hwang, Jiann-Loung
    Ho, Low-Tone
    SEMINARS IN REPRODUCTIVE MEDICINE, 2008, 26 (01) : 101 - 110
  • [29] Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health
    Brennan, Kathleen M.
    Kroener, Lindsay L.
    Chazenbalk, Gregorio D.
    Dumesic, Daniel A.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2019, 74 (04) : 223 - 231
  • [30] Endocrine and metabolic effects of dexfenfluramine in obese women with polycystic ovary syndrome
    Acbay, O
    Gundogdu, S
    DIABETOLOGIA, 1996, 39 : 854 - 854